Legal entity
GLP-1 Receptor Agonists is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in corporate-law, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 2 original sources on average.
Last mentioned: 3d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
GLP-1 Receptor Agonists is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in corporate-law, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 2 original sources on average. We currently track 2 Legal stories that mention NAION, all published on September 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 10 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NAION. Shared-story counts are live from our verified record — not editorial picks.
Civil lawsuit against Novo Nordisk reported
The Wall Street Journal reported a civil lawsuit filed against Novo Nordisk by patients who developed NAION after taking Wegovy or Ozempic; similar cases against Eli Lilly are pending.
AAO issues statement on GLP-1s and vision loss
The American Academy of Ophthalmology released a news release urging clinicians and patients to make informed choices about GLP-1 use after studies linked the drugs to vision loss.
First NAION lawsuits filed against GLP-1 makers in New Jersey
Patients begin filing lawsuits alleging that GLP-1 drugs such as Ozempic, Wegovy, and Zepbound caused permanent vision loss and that manufacturers failed to warn about the risk.
Boston medical center issues safety alert
Researchers at a Boston medical facility sent a safety alert flagging a possible connection between GLP-1 medications and NAION.
Nearly 100 NAION lawsuits against Novo Nordisk and Eli Lilly test pharmaceutical failure-to-warn liability. Mixed epidemiological evidence and diabetes-related blindness risk create a dense causation battleground for mass tort litigators.
Mass tort litigation against Novo Nordisk and Eli Lilly is escalating, with nearly 1,000 cases in New Jersey alone alleging the companies failed to warn patients about NAION risk.
NAION is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
